Tyra Biosciences adds Habib Dable to board
Tyra Biosciences, Inc. expanded its board of directors from nine to ten members and appointed Habib J. Dable as a Class II director, with his initial term ending at the company’s 2026 annual meeting of stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Tyra Biosciences, Inc. expanded its board of directors from nine to ten members and appointed Habib J. Dable as a Class II director, with his initial term ending at the company’s 2026 annual meeting of stockholders. The board determined he qualifies as an independent director under Nasdaq rules.
In connection with his appointment, Dable received options to purchase 44,400 shares of Tyra’s common stock at the fair market value on the grant date, vesting in equal monthly installments over 36 months. He will also receive cash compensation under the company’s Non-Employee Director Compensation Program and has entered into Tyra’s standard indemnification agreement.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board size after change: 10 directors
Previous board size: 9 directors
Stock options granted: 44,400 shares
+2 more
5 metrics
Board size after change
10 directors
Board increased from nine to ten members
Previous board size
9 directors
Number of authorized directors before increase
Stock options granted
44,400 shares
Options granted to Habib J. Dable upon board appointment
Vesting period
36 months
Monthly vesting schedule for Dable’s stock options
Director age
56 years
Age of Habib J. Dable at time of appointment
Key Terms
Class II director, Non-Employee Director Compensation Program, indemnification agreement, independent director, +1 more
5 terms
Class II director financial
"appointed Habib J. Dable to the Board as a Class II director with an initial term"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
Non-Employee Director Compensation Program financial
"pursuant to the Company’s Non-Employee Director Compensation Program, Mr. Dable was granted options"
indemnification agreement regulatory
"Mr. Dable entered into the Company’s standard form of indemnification agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
independent director regulatory
"The Board has determined that Mr. Dable is an independent director in accordance with the listing requirements"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Nasdaq Global Select Market financial
"Common Stock, par value $0.0001 per share | | TYRA | | Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tyra Biosciences (TYRA) announce about its board of directors?
Tyra Biosciences expanded its board from nine to ten directors and appointed Habib J. Dable as a Class II director. His initial term runs until the company’s 2026 annual meeting of stockholders, increasing the board’s size while adding additional industry experience.
Who is Habib J. Dable, the new director at Tyra Biosciences (TYRA)?
Habib J. Dable is a 56-year-old biopharmaceutical executive and advisor at RA Capital Management. He previously served as President and CEO of Acceleron Pharma and held senior leadership roles at Bayer, including President of U.S. Pharmaceuticals and Global Head of Specialty Medicine.
What equity compensation did Habib J. Dable receive from Tyra Biosciences (TYRA)?
In connection with joining the board, Habib J. Dable received options to purchase 44,400 shares of Tyra Biosciences common stock. The options are priced at the fair market value on the grant date and vest in substantially equal monthly installments over 36 months.
How will Habib J. Dable’s stock options at Tyra Biosciences (TYRA) vest?
Habib J. Dable’s options to buy 44,400 Tyra Biosciences shares will vest in substantially equal monthly installments. The vesting period runs over 36 months following the grant date, aligning his equity compensation with multi-year board service and ongoing company performance.
Is Habib J. Dable considered an independent director at Tyra Biosciences (TYRA)?
Yes. The board of Tyra Biosciences determined that Habib J. Dable qualifies as an independent director. This determination was made in accordance with the listing requirements of The Nasdaq Stock Market LLC, supporting standard governance and independence practices for the company’s board.
What other compensation and protections does Habib J. Dable receive from Tyra Biosciences (TYRA)?
Beyond stock options, Habib J. Dable will receive cash compensation under Tyra’s Non-Employee Director Compensation Program. He also entered into the company’s standard indemnification agreement, which offers legal protection for his board service as previously filed with Tyra’s annual report on Form 10-K.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates